Inclusion Criteria:

          -  For all parts: The participant must be, in the judgment of the investigator, an
             appropriate candidate for experimental therapy after available standard therapies have
             failed to provide clinical benefit for their advanced or metastatic cancer.

               -  For dose escalation for all combinations: The participant must have histological
                  or cytological evidence of cancer, either a solid tumor or a lymphoma, which is
                  advanced or metastatic.

               -  For Part A dose confirmation: All participants must have histological evidence of
                  advanced or metastatic soft tissue sarcoma or breast cancer. Breast cancer
                  participants must have prescreened mutations, amplification, or gene/protein
                  expression alterations related to Notch pathway.

               -  For Part B dose confirmation: All participants must have histological evidence of
                  advanced or metastatic colon cancer or soft tissue sarcoma. Colon cancer
                  participants must have prescreened mutations, amplification, or gene/protein
                  expression alterations related to Notch pathway.

               -  For Part C dose confirmation: All participants must have histological evidence of
                  advanced or metastatic breast cancer and prescreened mutations, amplification, or
                  gene/protein expression alterations related to Notch pathway.

               -  For Part D dose confirmation: All participants must have histological evidence of
                  cholangiocarcinoma and prescreened mutations, amplification, or gene/protein
                  expression alterations related to Notch pathway. Participants must not have
                  received >1 line of prior systemic therapy for metastatic or resectable disease
                  (that is, participants may have received adjuvant gemcitabine and then later
                  gemcitabine/cisplatin for recurrent metastatic disease).

               -  For Part E dose confirmation: All participants must have histological evidence of
                  locally advanced or metastatic triple negative breast cancer (TNBC) and
                  prescreened mutations, amplification, or gene/protein expression alterations
                  related to Notch pathway. Participants must not have received >2 lines of
                  systemic treatment for advanced or metastatic TNBC.

          -  Have adequate organ function.

          -  Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

          -  Have discontinued all previous therapies for cancer.

        Exclusion Criteria:

          -  Have current acute leukemia.

          -  Have current or recent (within 3 months of study drug administration) gastrointestinal
             disease with chronic or intermittent diarrhea, or disorders that increase the risk of
             diarrhea, such as inflammatory bowel disease.